🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Transformative Research in Diabetic Nephropathy 2.0

Recruitingn/aAges 18 Years - anyAllUniversity of Pennsylvania
NCT07444203 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to learn more about kidney health in adults with diabetic kidney disease and other groups. Researchers will study kidney tissue and other samples. They want to learn how sodium-glucose cotransporter-2 (SGLT2) inhibitors, a type of diabetes medicine, may affect the kidneys. People can join only if they are already having a kidney biopsy or kidney surgery as part of their regular medical care. The main questions this study aims to answer are: * Do people who take SGLT2 inhibitors show different biological patterns in kidney tissue than similar people who do not take them? * Are these kidney tissue patterns linked with how kidney health changes over time? Researchers will compare participants who take SGLT2 inhibitors with similar participants who do not take these medicines. Participants will: Let researchers use one stored slide of kidney tissu

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥18 years * eGFR ≥10 ml/min/1.73 m2 based on the 2021 race-free CKD-EPI equation13 * Underwent a clinically indicated kidney biopsy, living donor biopsy, or nephrectomy (non-tumor adjacent tissue available). * Able and willing to provide informed consent for release of one pathology and clinical data abstraction. Exclusion Criteria: * Inability to provide informed consent. * Archived biopsy or surgical tissue unavailable for slide preparation. * Any local institutional policy that prohibits release of H\&E slides for research.
💊

What it tests

  • Sodium-glucose cotransporter 2 inhibitors (SGLT2i)
  • Renin-angiotensin-aldosterone system blockade
  • Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
  • Mineralocorticoid Receptor Antagonists(MRAs)
📍

Where

1 site
Penn Presbyterian Medical Center
Philadelphia, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy